Lung Cancer
News from the FDA/CDC
Smoking-cessation attempts changed little over 7-year span
“Smokers should be encouraged to keep trying to quit until they succeed, and health care providers should be encouraged to keep supporting smokers...
From the Journals
Combo RT/pembro may show synergy in NSCLC
Findings from two phase 2 studies suggest possible synergy between immune checkpoint blockade and radiotherapy for patients with non–small cell...
From the Journals
Investigators target brain metastases in NSCLC
In a retrospective study of matched primary and metastases samples, PI3K signaling was associated with an increased risk of brain metastases, and...
From the Journals
Atezolizumab combo in first-line NSCLC misses cost-effectiveness mark
The incremental cost‐effectiveness ratio of ABCP as compared with BCP or with CP – more than $500,000 per QALY – far exceeded the conventional...
From the Journals
Frontline pembro + chemo shows superiority against NSCLC
In a retrospective study involving 16,228 patients with NSCLC, patients treated with immunotherapy had a significantly longer median overall...
Opinion
Predicting outcomes in acute leukemia, NSCLC
Dr. Alan Lyss examines the latest research on predicting VTE risk in patients with acute leukemia and new data on the impact of steroids in non–...
From the Journals
Vemurafenib has durable activity in NSCLC harboring BRAF V600 mutations
More than a third of patients had a complete or partial response to monotherapy with the oral BRAF(V600E) kinase inhibitor, and median overall...
From the Journals
Multigene panel sequencing is moderately cost-effective in NSCLC
Compared with a single-marker approach, a multigene panel approach had an incremental cost-effectiveness ratio of about $148,000 per life-year...
News
FDA approves bevacizumab-bvzr for several cancers
The bevacizumab biosimilar is now approved for metastatic colorectal cancer, advanced non-squamous non–small cell lung cancer, recurrent...
From the Journals
Liquid biopsy assays found sensitive for NSCLC EGFR mutations
Two liquid biopsy assays performed well at detecting EGFR mutations in plasma-derived cell-free DNA from patients with NSCLC, possibly...
From the Journals
Immunotherapy-treated NSCLC: Adverse impact of steroids driven by palliative indications
A new analysis suggests use of steroids for cancer-related palliation in patients with poor prognosis largely explains their association with...